Emma Asma Cornwall
All posts from Emma Asma Cornwall
Emma Asma Cornwall in Gainers & Losers,

Orexigen Therapeutics is worth looking into

Orexigen Therapeutics closed a record for the number of scripts in a quarter.

Its Contrave drug was the only branded anti-obesity drug in US to show growth - Belviq of Arena , and Qsymia of Vivus showed declines of sales qq in Q3. Contrave had qq growth of 8.86%. There's some more positive signs, and I can't say that fundamentals of the company are in perfect shape right now, but sometimes good technicals can be enough - and here we have a falling wedge, which was broken recently.

I'm cautiously expecting upside of this stock...